Next Article in Journal
Lysine-Specific Histone Demethylase 1 Inhibition Enhances Robust Fetal Hemoglobin Induction in Human β0-Thalassemia/Hemoglobin E Rrythroid Cells
Previous Article in Journal
Impact of Pharmacokinetics to Reduce Bleeding in a Cohort of Patients with Severe Hemophilia A in a Personalized Comprehensive Management Program
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Therapeutic Innovation for Multi-Resistant Candidemics: Synergy of Isavuconazole and Caspofungin Association

1
Post Graduation School of Hematology, University of Catania, A.O.U. ‘Policlinico-San Marco’, via S. Sofia 78, 95123 Catania, Italy
2
Division of Hematology, A.O.U. ‘Policlinico-San Marco’, Catania, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2021, 13(4), 9329; https://doi.org/10.4081/hr.2021.9329
Submission received: 22 July 2021 / Revised: 23 August 2021 / Accepted: 17 September 2021 / Published: 26 November 2021

Abstract

Fungal infections occurring in immunocompromised patients after immuno-chemotherapy treatment, are often difficult to eradicate and capable of even being fatal. Systemic mycoses affecting severely immunocompromised patients often manifest acutely with rapidly progressive pneumonia, fungemia, or manifestations of extrapulmonary dissemination. Opportunistic fungal infections (mycoses) include several pathogens elements, as Candidiasis, Aspergillosis, Mucormycosis (zygomycosis) and Fusariosis. Prompt diagnosis and effective therapy are needed to improve the associated morbidity and mortality, especially in cases with non-canonical fungal localizations and not responsive to the available antifungal drugs.
Keywords: fungal infection; Candida; isavuconazole; caspofungin; combined antifungal therapy; hematological patients fungal infection; Candida; isavuconazole; caspofungin; combined antifungal therapy; hematological patients

Share and Cite

MDPI and ACS Style

Duminuco, A.; Mauro, E.; Palumbo, G.A.M.; Garibaldi, B.; Parisi, M.; Di Raimondo, F.; Maugeri, C.; Vetro, C. Therapeutic Innovation for Multi-Resistant Candidemics: Synergy of Isavuconazole and Caspofungin Association. Hematol. Rep. 2021, 13, 9329. https://doi.org/10.4081/hr.2021.9329

AMA Style

Duminuco A, Mauro E, Palumbo GAM, Garibaldi B, Parisi M, Di Raimondo F, Maugeri C, Vetro C. Therapeutic Innovation for Multi-Resistant Candidemics: Synergy of Isavuconazole and Caspofungin Association. Hematology Reports. 2021; 13(4):9329. https://doi.org/10.4081/hr.2021.9329

Chicago/Turabian Style

Duminuco, Andrea, Elisa Mauro, Giuseppe A. M. Palumbo, Bruno Garibaldi, Marina Parisi, Francesco Di Raimondo, Cinzia Maugeri, and Calogero Vetro. 2021. "Therapeutic Innovation for Multi-Resistant Candidemics: Synergy of Isavuconazole and Caspofungin Association" Hematology Reports 13, no. 4: 9329. https://doi.org/10.4081/hr.2021.9329

APA Style

Duminuco, A., Mauro, E., Palumbo, G. A. M., Garibaldi, B., Parisi, M., Di Raimondo, F., Maugeri, C., & Vetro, C. (2021). Therapeutic Innovation for Multi-Resistant Candidemics: Synergy of Isavuconazole and Caspofungin Association. Hematology Reports, 13(4), 9329. https://doi.org/10.4081/hr.2021.9329

Article Metrics

Back to TopTop